| Phase 17 trials |
|
Phase 1
|
NCT07301723 |
Dec 2025 → Mar 2026 |
— |
Viatris Innovation GmbH |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05004311 |
Sep 2021 → Jul 2023 |
impaired renal function disease |
Viatris Innovation GmbH |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04819464 |
Aug 2021 → Aug 2024 |
— |
Viatris Innovation GmbH |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04255277 |
Jan 2020 → Sep 2021 |
— |
Viatris Innovation GmbH |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04052360 |
Aug → Oct 2019 |
— |
Viatris Innovation GmbH |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02914223 |
Sep → Dec 2016 |
— |
Viatris Innovation GmbH |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02479204 |
Apr 2015 → May 2016 |
— |
Viatris Innovation GmbH |
Terminated
|
No outcome recorded
|
| Phase 1/21 trial · 1 met primary |
|
Phase 1/2
|
NCT02472795 |
Jun 2015 → Jan 2017 |
systemic lupus erythematosus |
Viatris Innovation GmbH |
Completed
|
Met primary
|
| Phase 22 trials · 1 missed |
|
Phase 2
|
NCT07266090 |
Jan 2026 → Oct 2027 expected |
systemic lupus erythematosus |
Viatris Pharmaceuticals Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03742037 |
Dec 2018 → Aug 2021 |
systemic lupus erythematosus |
Viatris Innovation GmbH |
Completed
|
Missed primary
|
| Phase 34 trials |
|
Phase 3
|
NCT07201129 |
Feb 2026 → Aug 2029 expected |
lupus nephritis, systemic lupus erythematosus |
Viatris Innovation GmbH |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06475742 |
Jul 2024 → Sep 2032 expected |
systemic lupus erythematosus |
Viatris Innovation GmbH |
Enrolling by invitation
|
No outcome recorded
|
|
Phase 3
|
NCT05672576 |
Jun 2023 → Dec 2026 expected |
systemic lupus erythematosus |
Viatris Innovation GmbH |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05648500 |
Dec 2022 → Mar 2027 expected |
systemic lupus erythematosus |
Viatris Innovation GmbH |
Active not recruiting
|
No outcome recorded
|